In search of value $KYMR:
A look at the valuation of $KYMR.
A look at the valuation of $KYMR.
Cash = $596 million
IRAK4 is a very big indication. It could be worth $3 billion or more depending which indications it works out in. I don't think it works in all the indications they try, but it should work in most of them. They only have biomarker data so far.
IRAK4 is a very big indication. It could be worth $3 billion or more depending which indications it works out in. I don't think it works in all the indications they try, but it should work in most of them. They only have biomarker data so far.
They also have safety data. That would justify a .5 multiple due to some data. That would make this work $1.5 billion in value.
STAT3 could be another great indication with over $1 billion in sales. They have no data for this program yet so I would give it a .1 multiple for preclinic. That makes it worth $100 million in value.
Their last program is MDM2 for p53 cancers. This should be worth over $1 billion depending on the data. This is very early in preclinic. I would give it a .1 multiplier. That makes it worth $100 million value.
All in, I get to $2.296 billion valuation. They have about 54.9 million shares outstanding. That comes to $41.82. That makes this company extremely undervalued by -35%.
Loading suggestions...